Publications

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.

01-12-2018

Investigational new drugs

Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose.

01-12-2018

Breast (Edinburgh, Scotland)

Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy.

01-12-2018

British journal of clinical pharmacology

Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers.

01-12-2018

Journal of pharmaceutical and biomedical analysis

Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates.

30-11-2018

Molecular pharmaceutics

ABCB1 Attenuates the Brain Penetration of the PARP Inhibitor AZD2461.

05-11-2018

Molecular pharmaceutics

P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.

05-11-2018

The Lancet. Oncology

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.

01-11-2018

Breast cancer research and treatment

Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen.

01-11-2018

Pharmacological research

P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.

01-11-2018

International journal of cancer

P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.

15-10-2018

Nucleosides, nucleotides & nucleic acids

Development and validation of a quantitative method for thymidine phosphorylase activity in peripheral blood mononuclear cells.

05-10-2018

Journal of pharmaceutical and biomedical analysis

Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine.

05-09-2018

Cancer chemotherapy and pharmacology

Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of ¹⁴C-plitidepsin.

01-09-2018

The Journal of antimicrobial chemotherapy

Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure-response relationships.

01-08-2018

Marine drugs

Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment.

23-07-2018

Scientific reports

Buparlisib is a brain penetrable pan-PI3K inhibitor.

17-07-2018

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Bioanalysis of ibrutinib, and its dihydrodiol- and glutathione cycle metabolites by liquid chromatography-tandem mass spectrometry.

15-07-2018

Contact dermatitis

Palladium-induced granulomas analysed with inductively coupled plasma mass spectrometry.

01-07-2018

Neoplasia (New York, N.Y.)

Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2.

01-07-2018

Frontiers in cellular and infection microbiology

Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis.

19-06-2018

International journal of pharmaceutics

Solubility and bioavailability improvement of pazopanib hydrochloride.

10-06-2018

European journal of clinical pharmacology

The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases.

01-06-2018

British journal of clinical pharmacology

Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.

01-06-2018

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood-Brain Barrier Using Elacridar and ¹¹C-Erlotinib PET.

01-06-2018

Investigational new drugs

ATP-binding cassette transporters limit the brain penetration of Wee1 inhibitors.

01-06-2018

Cell

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.

31-05-2018

Bioorganic & medicinal chemistry letters

A multi-gram-scale stereoselective synthesis of Z-endoxifen.

01-05-2018

Clinical pharmacokinetics

Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial.

01-05-2018

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry.

15-04-2018

Clinical pharmacokinetics

PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.

01-04-2018

Biomedical chromatography : BMC

Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs.

01-04-2018

Therapeutic drug monitoring

Fast and Straightforward Method for the Quantification of Pazopanib in Human Plasma Using LC-MS/MS.

01-04-2018

Journal of pharmaceutical and biomedical analysis

Ultra-sensitive LC-MS/MS method for the quantification of gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma for a microdose clinical trial.

20-03-2018

Journal of neuro-oncology

EpCAM-based assays for epithelial tumor cell detection in cerebrospinal fluid.

01-03-2018

Pharmacological research

P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice.

01-03-2018

Clinical pharmacokinetics

Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs.

01-02-2018

Journal of pharmaceutical and biomedical analysis

Thermal stability study of crystalline and novel spray-dried amorphous nilotinib hydrochloride.

30-01-2018

Journal of pharmaceutical and biomedical analysis

Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of Dexamphetamine in human plasma.

30-01-2018

International journal of cancer

The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors.

15-01-2018

Cancer chemotherapy and pharmacology

Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a ¹⁴C-microtracer and therapeutic dose in cancer patients.

01-01-2018

Cancer chemotherapy and pharmacology

Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a ¹⁴C-microtracer and therapeutic dose in cancer patients.

01-01-2018

Annals of oncology : official journal of the European Society for Medical Oncology

DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update.

01-12-2017

Cancer chemotherapy and pharmacology

Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization.

01-12-2017

Investigational new drugs

Human mass balance study and metabolite profiling of ¹⁴C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer.

01-12-2017

Thrombosis and haemostasis

Enrichment of Circulating Endothelial Cells by CD34 Microbeads Followed by Enumeration Using Flow Cytometry.

01-12-2017

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

An LC-MS/MS method for quantification of the active abiraterone metabolite Δ(4)-abiraterone (D4A) in human plasma.

15-11-2017

Clinical pharmacology and therapeutics

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.

01-11-2017

The Journal of antimicrobial chemotherapy

Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study.

01-11-2017

European journal of cancer (Oxford, England : 1990)

A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir.

01-11-2017

Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.

Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose.

Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy.

Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers.

Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates.

ABCB1 Attenuates the Brain Penetration of the PARP Inhibitor AZD2461.

P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.

Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen.

P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.

P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.

Development and validation of a quantitative method for thymidine phosphorylase activity in peripheral blood mononuclear cells.

Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine.

Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of 14C-plitidepsin.

Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure-response relationships.

Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment.

Buparlisib is a brain penetrable pan-PI3K inhibitor.

Bioanalysis of ibrutinib, and its dihydrodiol- and glutathione cycle metabolites by liquid chromatography-tandem mass spectrometry.

Palladium-induced granulomas analysed with inductively coupled plasma mass spectrometry.

Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2.

Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis.

Solubility and bioavailability improvement of pazopanib hydrochloride.

The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases.

Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.

Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood-Brain Barrier Using Elacridar and 11C-Erlotinib PET.

ATP-binding cassette transporters limit the brain penetration of Wee1 inhibitors.

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.

A multi-gram-scale stereoselective synthesis of Z-endoxifen.

Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial.

Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry.

PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.

Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs.

Fast and Straightforward Method for the Quantification of Pazopanib in Human Plasma Using LC-MS/MS.

Ultra-sensitive LC-MS/MS method for the quantification of gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma for a microdose clinical trial.

EpCAM-based assays for epithelial tumor cell detection in cerebrospinal fluid.

P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice.

Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs.

Thermal stability study of crystalline and novel spray-dried amorphous nilotinib hydrochloride.

Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of Dexamphetamine in human plasma.

The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors.

Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients.

Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients.

DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update.

Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization.

Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer.

Enrichment of Circulating Endothelial Cells by CD34 Microbeads Followed by Enumeration Using Flow Cytometry.

An LC-MS/MS method for quantification of the active abiraterone metabolite Δ(4)-abiraterone (D4A) in human plasma.

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.

Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study.

A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir.

This site uses cookies

Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of ¹⁴C-plitidepsin.

Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood-Brain Barrier Using Elacridar and ¹¹C-Erlotinib PET.

Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a ¹⁴C-microtracer and therapeutic dose in cancer patients.

Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a ¹⁴C-microtracer and therapeutic dose in cancer patients.

Human mass balance study and metabolite profiling of ¹⁴C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer.